Antimalarial (8-aminoquinoline)
8-aminoquinoline antimalarial indicated for radical cure (prevention of relapse) of Plasmodium vivax malaria in patients ≥ 16 years receiving chloroquine for acute P. vivax infection.
Also known as: Krintafel
DailyMed approved label (KRINTAFEL, tafenoquine succinate; setID 5cf989d5-36f5-4561-a30b-9fcb9deb6b6a).
DailyMed approved label (KRINTAFEL, tafenoquine succinate; setID 5cf989d5-36f5-4561-a30b-9fcb9deb6b6a).
No documented drug–drug interactions for this medicine.
Alcohol may worsen the psychiatric effects (insomnia, anxiety, abnormal dreams) of tafenoquine; limit intake.
Limit alcohol intake during treatment.
DailyMed/FDA (NIH/NLM) — approved Tafenoquine label (KRINTAFEL): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cf989d5-36f5-4561-a30b-9fcb9deb6b6a
Tafenoquine can be taken with or without food; taking with food reduces gastrointestinal discomfort.
Take with food if gastric discomfort occurs.
DailyMed/FDA (NIH/NLM) — approved Tafenoquine label (KRINTAFEL): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cf989d5-36f5-4561-a30b-9fcb9deb6b6a
Tafenoquine causes psychiatric effects (insomnia, anxiety, depression, abnormal dreams); use with caution in patients with psychiatric disease.
Monitor psychiatric symptoms; stop with severe symptoms.
DailyMed/FDA (NIH/NLM) — approved Tafenoquine label (KRINTAFEL): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cf989d5-36f5-4561-a30b-9fcb9deb6b6a
Tafenoquine causes severe haemolysis in patients with G6PD deficiency; it is contraindicated in deficiency or when G6PD status is unknown.
Mandatory G6PD screening before prescribing; contraindicated in deficiency or unknown status.
DailyMed/FDA (NIH/NLM) — approved Tafenoquine label (KRINTAFEL): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cf989d5-36f5-4561-a30b-9fcb9deb6b6a
Tafenoquine is contraindicated in pregnancy: the fetal G6PD status is unknown and there is a risk of severe fetal haemolysis.
Contraindicated in pregnancy; postpone radical cure until after delivery.
Contraindicated in breastfeeding if the infant is G6PD deficient or of unknown status.
Advise effective contraception during treatment.
DailyMed/FDA (NIH/NLM) — approved Tafenoquine label (KRINTAFEL): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cf989d5-36f5-4561-a30b-9fcb9deb6b6a
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
8-aminoquinoline antimalarial active against liver hypnozoites of P. vivax; does not prolong the QTc interval to a clinically relevant extent even at a cumulative dose of 1,200 mg (4x the maximum recommended dose).
Mechanism similar to other 8-aminoquinolines: inhibition of mitochondrial function and oxidative stress in dormant liver stages of the parasite, preventing relapse.
Maximum plasma concentrations generally 12–15 hours after oral administration; food increases plasma AUC.
Extensively metabolized; elimination is slow (long half-life), allowing single-dose administration.
Elimination half-life of ~15 days.
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
